ClinicalTrials.gov
public full text
Public Domain
DALY II Japan/MB-CART2019.1 for DLBCL
DALY II Japan is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) in patients with relapsed and/or refractory diffuse large B cell lymphoma (DLBCL) after receiving at least two lines of therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL#1095659
- Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma#847444
- Cellular therapy in older adults with relapsed/refractory diffuse large B-cell lymphoma#1174781
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma#834525
- Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas#1100470
Record · ID 906772
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive